256 related articles for article (PubMed ID: 28855104)
1. FoxM1: Repurposing an oncogene as a biomarker.
Nandi D; Cheema PS; Jaiswal N; Nag A
Semin Cancer Biol; 2018 Oct; 52(Pt 1):74-84. PubMed ID: 28855104
[TBL] [Abstract][Full Text] [Related]
2. Forkhead box M1 (FOXM1) expression predicts disease free survival and may mediate resistance to chemotherapy and hormonotherapy in male breast cancer.
Abdeljaoued S; Bettaieb L; Nasri M; Adouni O; Goucha A; Bouzaiene H; Boussen H; Rahal K; Gamoudi A
Breast Dis; 2018; 37(3):109-114. PubMed ID: 29504520
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas.
Maekawa A; Kohashi K; Kuda M; Iura K; Ishii T; Endo M; Nakatsura T; Iwamoto Y; Oda Y
BMC Cancer; 2016 Jul; 16():511. PubMed ID: 27439614
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of FOXM1 in solid tumors: a systematic review and meta-analysis.
Li L; Wu D; Yu Q; Li L; Wu P
Oncotarget; 2017 May; 8(19):32298-32308. PubMed ID: 28427178
[TBL] [Abstract][Full Text] [Related]
5. FOXM1 predicts disease progression in non-muscle invasive bladder cancer.
Rinaldetti S; Wirtz R; Worst TS; Hartmann A; Breyer J; Dyrskjot L; Erben P
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1701-1709. PubMed ID: 29959570
[TBL] [Abstract][Full Text] [Related]
6. FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes.
Rinaldetti S; Wirtz RM; Worst TS; Eckstein M; Weiss CA; Breyer J; Otto W; Bolenz C; Hartmann A; Erben P
Oncotarget; 2017 Jul; 8(29):47595-47606. PubMed ID: 28498805
[TBL] [Abstract][Full Text] [Related]
7. MiR-216b inhibits cell proliferation by targeting FOXM1 in cervical cancer cells and is associated with better prognosis.
He S; Liao B; Deng Y; Su C; Tuo J; Liu J; Yao S; Xu L
BMC Cancer; 2017 Oct; 17(1):673. PubMed ID: 28978307
[TBL] [Abstract][Full Text] [Related]
8. ADAM-17 is a poor prognostic indicator for patients with hilar cholangiocarcinoma and is regulated by FoxM1.
Jiao X; Yu W; Qian J; Chen Y; Wei P; Fang W; Yu G
BMC Cancer; 2018 May; 18(1):570. PubMed ID: 29776401
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
[TBL] [Abstract][Full Text] [Related]
10. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy.
Wierstra I
Adv Cancer Res; 2013; 119():191-419. PubMed ID: 23870513
[TBL] [Abstract][Full Text] [Related]
11. Aberrantly high activation of a FoxM1-STMN1 axis contributes to progression and tumorigenesis in FoxM1-driven cancers.
Liu J; Li J; Wang K; Liu H; Sun J; Zhao X; Yu Y; Qiao Y; Wu Y; Zhang X; Zhang R; Yang A
Signal Transduct Target Ther; 2021 Feb; 6(1):42. PubMed ID: 33526768
[TBL] [Abstract][Full Text] [Related]
12. Targeting forkhead box M1 transcription factor in breast cancer.
O'Regan RM; Nahta R
Biochem Pharmacol; 2018 Aug; 154():407-413. PubMed ID: 29859987
[TBL] [Abstract][Full Text] [Related]
13. Transcription factor FoxM1 is the downstream target of c-Myc and contributes to the development of prostate cancer.
Pan H; Zhu Y; Wei W; Shao S; Rui X
World J Surg Oncol; 2018 Mar; 16(1):59. PubMed ID: 29554906
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of FoxM1 by MnSOD Overexpression Contributes to Cancer Stem-Like Cell Characteristics in the Lung Cancer H460 Cell Line.
Fu Z; Cao X; Yang Y; Song Z; Zhang J; Wang Z
Technol Cancer Res Treat; 2018 Jan; 17():1533033818789635. PubMed ID: 30111255
[TBL] [Abstract][Full Text] [Related]
15. HGF/Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes.
Cui J; Xia T; Xie D; Gao Y; Jia Z; Wei D; Wang L; Huang S; Quan M; Xie K
Oncogene; 2016 Sep; 35(36):4708-18. PubMed ID: 26876216
[TBL] [Abstract][Full Text] [Related]
16. A Positive Feedback Loop of lncRNA-
Xu MD; Wang Y; Weng W; Wei P; Qi P; Zhang Q; Tan C; Ni SJ; Dong L; Yang Y; Lin W; Xu Q; Huang D; Huang Z; Ma Y; Zhang W; Sheng W; Du X
Clin Cancer Res; 2017 Apr; 23(8):2071-2080. PubMed ID: 27756785
[No Abstract] [Full Text] [Related]
17. FOXM1: From cancer initiation to progression and treatment.
Koo CY; Muir KW; Lam EW
Biochim Biophys Acta; 2012 Jan; 1819(1):28-37. PubMed ID: 21978825
[TBL] [Abstract][Full Text] [Related]
18. Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia.
Liu LL; Zhang DH; Mao X; Zhang XH; Zhang B
Biochem Biophys Res Commun; 2014 Mar; 446(1):280-5. PubMed ID: 24582753
[TBL] [Abstract][Full Text] [Related]
19. Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer.
Francica P; Nisa L; Aebersold DM; Langer R; Bladt F; Blaukat A; Stroka D; Martínez MR; Zimmer Y; Medová M
Clin Cancer Res; 2016 Nov; 22(21):5322-5336. PubMed ID: 27185371
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of forkhead box protein M1 (FOXM1) plays a critical role in colorectal cancer.
Zhang HG; Xu XW; Shi XP; Han BW; Li ZH; Ren WH; Chen PJ; Lou YF; Li B; Luo XY
Clin Transl Oncol; 2016 May; 18(5):527-32. PubMed ID: 26370421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
